Watch SGMOQ. Know when insiders buy.
One email the day a filing lands. Free.
SGMOQ
SANGAMO THERAPEUTICS, INC
0.15
+0.01 +4.64%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
38
FLAG · shorts 38
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $60.7MP/E —DIV YIELD —FCF YIELD -149.04%REV TTM $34.6M −45.8%NET INCOME −$123.3MNET CASH —52W 0.04 – 0.74SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2026 · Mar 31 | $1.4M | −77.6% | — | −$31.9M | −$31M | — | -0.08 | −$19.3M | $13K | −$19.3M | May 14 |
| Q4 2025 · Dec 31derived | $14.2M | +88.4% | — | −$38.2M | −$37.4M | — | -0.11 | −$24.4M | $14K | −$24.4M | Mar 30 |
| Q3 2025 · Sep 30 | $581K | −98.8% | — | −$35.6M | −$34.9M | −427.3% | -0.11 | −$28.5M | $64K | −$28.6M | Nov 6 |
| Q2 2025 · Jun 30 | $18.3M | +5042.1% | — | −$17.9M | −$20M | — | -0.08 | −$18.2M | $24K | −$18.2M | Aug 7 |
| Q1 2025 · Mar 31 | $6.4M | +1238.3% | — | −$29.6M | −$30.6M | — | -0.14 | −$26.1M | $0 | −$26.1M | May 14 |
| Q4 2024 · Dec 31derived | $7.6M | +269.8% | — | −$26M | −$23.4M | — | -0.12 | −$3.4M | $152K | −$3.5M | Mar 30 |
| Q3 2024 · Sep 30 | $49.4M | +425.8% | — | $10.6M | $10.7M | — | 0.04 | $11.8M | $115K | $11.6M | Nov 6 |
| Q2 2024 · Jun 30 | $356K | −94.8% | — | −$37.1M | −$36.1M | — | -0.18 | −$26.9M | $0 | −$26.9M | Aug 7 |
| Q1 2024 · Mar 31 | $481K | — | — | −$51.5M | −$49.1M | — | -0.27 | −$48.7M | $0 | −$48.7M | May 12 |
| Q4 2023 · Dec 31derived | $2M | — | — | −$62.1M | −$60.3M | — | -0.34 | −$50.5M | $2.7M | −$53.2M | Mar 17 |
| Q3 2023 · Sep 30 | $9.4M | — | — | −$106.4M | −$104.2M | — | -0.59 | −$47.3M | $2.7M | −$50M | Nov 12 |
| Q2 2023 · Jun 30 | $6.8M | — | — | −$123.6M | −$114.5M | — | -0.66 | −$60.7M | $5.5M | −$66.3M | Aug 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $39.6M | — | −$121.2M | −$122.9M | -310.8% | -0.44 | −$97.2M | $102K | −$97.3M | — | — |
| FY2024 · to Dec 31 | $57.8M | — | −$104M | −$97.9M | -169.4% | -0.49 | −$67.1M | $267K | −$67.4M | — | — |
| FY2023 · to Dec 31 | $176.2M | — | −$274M | −$257.8M | -146.3% | -1.48 | −$224.8M | $21.2M | −$246M | — | — |
| FY2022 · to Dec 31 | $111.3M | — | −$201.3M | −$192.3M | -172.8% | -1.25 | −$223.6M | $20.2M | −$243.8M | — | — |
| FY2021 · to Dec 31 | $110.7M | — | −$183.3M | −$178.3M | -161.1% | -1.23 | −$233.3M | $23.3M | −$256.5M | — | — |
| FY2020 · to Dec 31 | $118.2M | — | −$129.6M | −$121M | -102.4% | -0.90 | $169.9M | $14.7M | $155.2M | — | — |
Every number comes from SANGAMO THERAPEUTICS, INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.